GrantRover ↗

← Alle Förderungen

Defense Health Agency Contracting Activity - DHACA · USA

DoW Breast Cancer, Breakthrough Award Levels 1 and 2

Offen

Defense Health Agency Contracting Activity - DHACA plant 6 Förderungen bei einem Gesamtbudget von 10,6 Mio. $. Die Einreichungsfrist endet am 18. November 2026. Antragsberechtigte Gruppen laut Quelle: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".

Frist
18. November 2026 (in 3 Tagen)
Fördersumme
≈ 1,77 Mio. $ pro Förderung (Schätzung: Gesamtbudget ÷ 6)
Gesamtbudget
10,6 Mio. $
Förderquote
Kein Pflicht-Eigenanteil angegeben; Förderquote nicht angegeben
Gesamtbudget
10,6 Mio. $
Erwartete Förderungen
6
Eigenanteil
Nicht erforderlich
Wahrscheinliche Antragstellende
Unternehmen, KMU / Start-ups, Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen, Einzelpersonen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber
Defense Health Agency Contracting Activity - DHACA
Referenz
HT942526BCRPBTA122
Assistance Listing (USA)
12.420 Military Medical Research and Development
Zuletzt geprüft
13. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Über diese Ausschreibung

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2.

Distinctive Features:

* This funding mechanism allows for applications submitted under Funding Level 1 or Funding Level 2. Funding Level 2 also includes a Population Science Studies option. With compelling justification, population science studies may request higher levels of funding and an additional year in the period of performance.

Vollständigen Text lesen

* This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Wer kann sich bewerben?

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Science and Technology and other Research and Development

So bewerben Sie sich

  1. Read the full notice of funding opportunity (NOFO) linked from the official page: eligibility, cost sharing and evaluation criteria.
  2. Make sure your organisation has an active SAM.gov registration and Unique Entity ID (UEI); registration can take several weeks.
  3. Register with Grants.gov and set up a Workspace for this opportunity, with the right roles for your organisation.
  4. Prepare the required forms, narrative, budget and attachments exactly as the NOFO specifies.
  5. Submit before the deadline and keep the tracking number. Check for amendments before you submit.

From the call text

Who can apply
Not stated in the call text we hold — check the official page
Company stage
Not stated in the call text we hold — check the official page
Single applicant or consortium
Not stated in the call text we hold — check the official page
Where applicants must be based
Not stated in the call text we hold — check the official page
Where to apply
Not stated in the call text we hold — check the official page

Kontakt

Danielle Reckley · help@eBRAP.org · 301-619-1139

Offizielle Quellen

Offizielle Ausschreibungsseite

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 13. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.

Weitere Ausschreibungen: Defense Health Agency Contracting Activity - DHACA

Defense Health Agency Contracting Activity - DHACA USA

DoW Joint Warfighter Medical, Military Medical Research and Development Award

HT942526JWMRPMMRDA

Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fu…

Defense Health Agency Contracting Activity - DHACA USA

DoW Breast Cancer, Clinical Research Extension Award

HT942526BCRPCREA2

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up…

Defense Health Agency Contracting Activity - DHACA USA

DOW Combat Readiness – Medical Research Program Translational Research Award

HT942526CRRPTRA

Summary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-imp…

Defense Health Agency Contracting Activity - DHACA USA

DoW Orthopaedic, Applied Research Award

HT942526ORPARA

Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of…

Defense Health Agency Contracting Activity - DHACA USA

DoW Orthopaedic, Clinical Research Award

HT942526ORPCRA

Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors …